Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.57 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GPR183 | P32249 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514668 | 1.00 | NNMT (0.70) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL1092124 | 0.87 | NNMT (0.73) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL34467327 | 0.87 | NNMT (0.73) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL18228074 | 0.86 | NNMT (0.72) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL12641872 | 0.85 | MKNK1 (0.73) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL30280631 | 0.85 | MKNK1 (0.73) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL29757598 | 0.84 | NNMT (0.70) | NNMTMKNK1MKNK2MAPTOXTR | |
| SCHEMBL185291 | 0.84 | NNMT (0.70) | NNMTMKNK1MKNK2MAPTOXTR | |
| SCHEMBL1515192 | 0.83 | NNMT (0.63) | NNMTMKNK1MKNK2NPC1RAB9A | |
| SCHEMBL25172927 | 0.83 | MAPT (0.52) | NNMTRAB9AMAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | GENZYME CORPORATION | 2025-12-23 | — | — | US | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| EP-4605388-A1 | <SUP2/>? <SUB2/>?3?2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CXCR1 | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| US-20250243177-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-3790876-B1 | ENDOPARASITIC DEPSIPEPTIDES | ZOETIS SERVICES LLC (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006122154-A2 | PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1678160-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Astellas Pharma Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006047397-A1 | THIENO-PYRIMIDINE COMPOUNDS HAVING FUNGICIDAL ACTIVITY | DOW AGROSCIENCES LLC (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089370-A1 | Thieno-pyrimidine compounds having fungicidal activity | BREWSTER WILLIAM K | 2006-04-27 | — | — | US | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| WO-2005040151-A1 | PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | ASTELLAS PHARMA INC. (JP) | 2005-05-06 | — | — | WO | disclosed |
| CN-1056840-C | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | NNMT 942/4885MKNK1 4103/4885MKNK2 4112/4885 |
| US-20060089370-A1 | Thieno-pyrimidine compounds having fungicidal activity | TYMP, DPM1, TYMS | NNMT 123/4885MKNK1 3287/4885MKNK2 3344/4885 |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | NNMT 2463/4885MKNK1 1752/4885MKNK2 1230/4885 |
| US-12612396-B1 | Modulators of beta catenin and uses thereof | CTNNB1, CTNND1, CTNNA1 | NNMT 3399/4885MKNK1 809/4885MKNK2 1213/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | NNMT 2989/4885MKNK1 943/4885MKNK2 407/4885 |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | NNMT 3399/4885MKNK1 809/4885MKNK2 1213/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | NNMT 2406/4885MKNK1 79/4885MKNK2 89/4885 |
| US-12503477-B2 | Colony stimulating factor-1 receptor (CSF-1R) inhibitors | CSF1R, CSF3R, IL1RN | NNMT 3719/4885MKNK1 1582/4885MKNK2 1786/4885 |
| US-20250243177-A1 | sGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | NNMT 1299/4885MKNK1 2446/4885MKNK2 2359/4885 |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | NNMT 1432/4885MKNK1 30/4885MKNK2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.